BMY Today - Aug 12: Merger Talk Fizzles Out

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

BMY Today - Aug 12: Merger Talk Fizzles Out

無料で聴く

ポッドキャストの詳細を見る

Hey, what’s up? It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today we're talking about Bristol-Myers Squibb, or BMY for short. So, how’d it go? Well, it was a bit of a snooze fest—BMY barely moved, closing up just a smidge, like 0.44%. Not exactly fireworks, right?

So, here’s the scoop. There’s been some chatter about a possible merger with AstraZeneca. But honestly, Wall Street isn't buying it. That talk seems to have fizzled out, and investors are feeling a bit skeptical. You know how it goes—when there’s uncertainty, people tend to hit the sell button fast. BMY's stock underperformed compared to its competitors today, which isn’t a great look. It’s like showing up to a party where everyone else is dressed to impress, and you’re in sweats. Yeah, that one stung.

And get this—Handelsbanken Fonder sold a ton of shares, almost half a million. That’s a pretty big move and probably shook some confidence. On the flip side, Wedge Capital is actually raising their stake in BMY, but that didn’t seem to help the stock much today. It’s like a mixed bag of vibes out there.

Now, on the horizon, Schrödinger, a company that's been in bed with BMY, just announced a solid Q2 profitability and their stock shot up over 19%. That could mean some good news for BMY down the line, but who knows? The market’s a wild ride.

So, to wrap it up, BMY had a pretty lackluster day, caught in the crossfire of merger talks that aren’t gaining any traction. It’s definitely a stock to keep an eye on, but remember, this is just for info and entertainment. Always do your own research before making any moves. Catch you later!

まだレビューはありません